取消对变异型克雅氏病风险的延迟:对新的和以前延迟的供体的影响。

IF 1.8 4区 医学 Q3 HEMATOLOGY
Vox Sanguinis Pub Date : 2025-03-24 DOI:10.1111/vox.70021
Mindy Goldman, David McKee, Shane Smith, Sheila F O'Brien
{"title":"取消对变异型克雅氏病风险的延迟:对新的和以前延迟的供体的影响。","authors":"Mindy Goldman, David McKee, Shane Smith, Sheila F O'Brien","doi":"10.1111/vox.70021","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Concern over variant Creutzfeldt-Jakob disease (vCJD) led to the deferral of donors who had resided in the United Kingdom since January 1980. This deferral was implemented in 1999 and subsequently modified to include other countries. Some deferrals were removed in February 2022; deferrals for the United Kingdom, Ireland and France were removed on 22 November 2023. In this study, we describe efforts made to encourage donation from newly eligible people and the resulting donation gain.</p><p><strong>Materials and methods: </strong>Actions targeted individual donors deferred after 1 January 2012. Marketing included website, social media and general advertising. Staff asked first-time donors if the criteria change had motivated their donation. Deferred and returning donor data were determined from our donor database.</p><p><strong>Results: </strong>In the 12 months post-implementation, 12.8% of first-time donors surveyed were newly eligible (n = 8667) and 7.8% of vCJD risk deferred donors returned (n = 5159). Eighty-five percent of deferrals occurred pre-2017; the return rate was 6.5% in this group. The highest return rate (24%) occurred in donors deferred after 2020.</p><p><strong>Conclusion: </strong>Removal of the vCJD deferrals had a major positive impact. The greatest gain was in new donors who had previously self-deferred. Despite intensive efforts, only one-quarter of recently deferred donors returned.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Removal of deferrals for variant Creutzfeldt-Jakob disease risk: Impact on new and previously deferred donors.\",\"authors\":\"Mindy Goldman, David McKee, Shane Smith, Sheila F O'Brien\",\"doi\":\"10.1111/vox.70021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>Concern over variant Creutzfeldt-Jakob disease (vCJD) led to the deferral of donors who had resided in the United Kingdom since January 1980. This deferral was implemented in 1999 and subsequently modified to include other countries. Some deferrals were removed in February 2022; deferrals for the United Kingdom, Ireland and France were removed on 22 November 2023. In this study, we describe efforts made to encourage donation from newly eligible people and the resulting donation gain.</p><p><strong>Materials and methods: </strong>Actions targeted individual donors deferred after 1 January 2012. Marketing included website, social media and general advertising. Staff asked first-time donors if the criteria change had motivated their donation. Deferred and returning donor data were determined from our donor database.</p><p><strong>Results: </strong>In the 12 months post-implementation, 12.8% of first-time donors surveyed were newly eligible (n = 8667) and 7.8% of vCJD risk deferred donors returned (n = 5159). Eighty-five percent of deferrals occurred pre-2017; the return rate was 6.5% in this group. The highest return rate (24%) occurred in donors deferred after 2020.</p><p><strong>Conclusion: </strong>Removal of the vCJD deferrals had a major positive impact. The greatest gain was in new donors who had previously self-deferred. Despite intensive efforts, only one-quarter of recently deferred donors returned.</p>\",\"PeriodicalId\":23631,\"journal\":{\"name\":\"Vox Sanguinis\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-03-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vox Sanguinis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/vox.70021\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.70021","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:对变异克雅氏病(vCJD)的担忧导致自1980年1月以来居住在联合王国的捐赠者推迟。这一推迟于1999年实施,随后进行了修改,纳入了其他国家。2022年2月取消了一些延期;英国、爱尔兰和法国的延期已于2023年11月22日取消。在本研究中,我们描述了鼓励新符合条件的人捐赠的努力和由此产生的捐赠收益。材料和方法:针对个人捐助者的行动推迟到2012年1月1日以后。营销包括网站、社交媒体和一般广告。工作人员询问首次捐赠的人,标准的改变是否促使他们捐赠。延迟和返回的供体数据是从我们的供体数据库中确定的。结果:在实施后的12个月内,12.8%的首次接受调查的献血者是新合格的(n = 8667), 7.8%的vCJD风险延期献血者返回(n = 5159)。85%的延期发生在2017年之前;这一组的回报率为6.5%。在2020年之后延期的捐助者中,回报率最高(24%)。结论:vCJD延期体的去除具有重要的积极影响。最大的收获是那些先前自我推迟的新捐赠者。尽管进行了密集的努力,最近推迟的捐助者中只有四分之一返回。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Removal of deferrals for variant Creutzfeldt-Jakob disease risk: Impact on new and previously deferred donors.

Background and objectives: Concern over variant Creutzfeldt-Jakob disease (vCJD) led to the deferral of donors who had resided in the United Kingdom since January 1980. This deferral was implemented in 1999 and subsequently modified to include other countries. Some deferrals were removed in February 2022; deferrals for the United Kingdom, Ireland and France were removed on 22 November 2023. In this study, we describe efforts made to encourage donation from newly eligible people and the resulting donation gain.

Materials and methods: Actions targeted individual donors deferred after 1 January 2012. Marketing included website, social media and general advertising. Staff asked first-time donors if the criteria change had motivated their donation. Deferred and returning donor data were determined from our donor database.

Results: In the 12 months post-implementation, 12.8% of first-time donors surveyed were newly eligible (n = 8667) and 7.8% of vCJD risk deferred donors returned (n = 5159). Eighty-five percent of deferrals occurred pre-2017; the return rate was 6.5% in this group. The highest return rate (24%) occurred in donors deferred after 2020.

Conclusion: Removal of the vCJD deferrals had a major positive impact. The greatest gain was in new donors who had previously self-deferred. Despite intensive efforts, only one-quarter of recently deferred donors returned.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Vox Sanguinis
Vox Sanguinis 医学-血液学
CiteScore
4.40
自引率
11.10%
发文量
156
审稿时长
6-12 weeks
期刊介绍: Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections: 1) Transfusion - Transmitted Disease and its Prevention: Identification and epidemiology of infectious agents transmissible by blood; Bacterial contamination of blood components; Donor recruitment and selection methods; Pathogen inactivation. 2) Blood Component Collection and Production: Blood collection methods and devices (including apheresis); Plasma fractionation techniques and plasma derivatives; Preparation of labile blood components; Inventory management; Hematopoietic progenitor cell collection and storage; Collection and storage of tissues; Quality management and good manufacturing practice; Automation and information technology. 3) Transfusion Medicine and New Therapies: Transfusion thresholds and audits; Haemovigilance; Clinical trials regarding appropriate haemotherapy; Non-infectious adverse affects of transfusion; Therapeutic apheresis; Support of transplant patients; Gene therapy and immunotherapy. 4) Immunohaematology and Immunogenetics: Autoimmunity in haematology; Alloimmunity of blood; Pre-transfusion testing; Immunodiagnostics; Immunobiology; Complement in immunohaematology; Blood typing reagents; Genetic markers of blood cells and serum proteins: polymorphisms and function; Genetic markers and disease; Parentage testing and forensic immunohaematology. 5) Cellular Therapy: Cell-based therapies; Stem cell sources; Stem cell processing and storage; Stem cell products; Stem cell plasticity; Regenerative medicine with cells; Cellular immunotherapy; Molecular therapy; Gene therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信